Capital Research & Management Co recently announced the acquisition of new stake in Gilead Sciences, Inc. (NASDAQ:GILD). The institutional investor has increased its shareholding in the Healthcare company by 0.98% to 81.72 million shares with purchase of 0.79 million shares. This fresh investment now brings its stake to 6.56% valued currently at $6.62 billion. In addition, BlackRock Fund Advisors raised its holdings by 0.29 million to 81.32 million shares. And Capital Research & Management Co has lifted its position by 0.02% or 14039.0 shares – to 57.91 million shares.
Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 70 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 39 of these insider trades were purchases, accounting for 158,682 shares. Insider sales of the common stock occurred on 31 occasions, with total insider shares sold totaling 105,681 shares.
The top 3 mutual fund holders in Gilead Sciences, Inc. are Vanguard Total Stock Market ETF, Fondo BBVA Bancomer USA 2 SA de C, and American Funds Income Fund of Ame. Vanguard Total Stock Market ETF owns 39.14 million shares of the company’s stock, all valued at over $3.17 billion. The company bought an additional 87579.0 shares recently to bring their total holdings to about 3.14% of the shares outstanding. American Funds Income Fund of Ame sold -1.19 million shares to bring its total holdings to over 33.25 million shares at a value of $2.69 billion. American Funds Income Fund of Ame now owns shares totaling to 2.67% of the shares outstanding.
However, the script later moved the day high at 80.00, down -0.57%. The company’s stock has a 5-day price change of 0.82% and 0.73% over the past three months. GILD shares are trading -2.39% year to date (YTD), with the 12-month market performance down to -5.44% lower. It has a 12-month low price of $72.87 and touched a high of $87.86 over the same period. GILD has an average intraday trading volume of 6.85 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.10%, -1.24%, and 0.73% respectively.
Institutional ownership of Gilead Sciences, Inc. (NASDAQ: GILD) shares accounts for 89.56% of the company’s 1.25B shares outstanding. Mutual fund holders own 29.74%, while other institutional holders and individual stakeholders account for 60.32% and 1.33% respectively.
It has a market capitalization of $98.52B and a beta (3y monthly) value of 0.21. The stock’s trailing 12-month PE ratio is 16.96, while the earnings-per-share (ttm) stands at $4.66. The company has a PEG of 4.11 and a Quick Ratio of 1.20 with the debt-to-equity ratio at 1.12. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.68% over the week and 1.85% over the month.
Analysts forecast that Gilead Sciences, Inc. (GILD) will achieve an EPS of $Gilead Sciences, Inc. for the current quarter, $79.07 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $SPDR Gold Trust while analysts give the company a high EPS estimate of $Gilat Satellite Networks Ltd.. Comparatively, EPS for the current quarter was $Gildan Activewear, Inc. a year ago. Earnings per share for the fiscal year are expected to decrease by -6.96%, and 7.03% over the next financial year. EPS should grow at an annualized rate of 4.12% over the next five years, compared to 0.73% over the past 5-year period.
Looking at the support for the GILD, a number of firms have released research notes about the stock. Deutsche Bank stated their Hold rating for the stock in a research note on November 09, 2023, with the firm’s price target at $75.
